<DOC>
	<DOC>NCT00093041</DOC>
	<brief_summary>The purpose of this trial is to determine the safety of zalutumumab as a treatment for head and neck cancer.</brief_summary>
	<brief_title>Zalutumumab in Head and Neck Cancer</brief_title>
	<detailed_description />
	<mesh_term>Head and Neck Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Squamous Cell</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>The study population eligible for this study is adult male or female patients of good performance status having a histologically confirmed recurrent or metastatic SCCHN, not amenable to standard curative or palliative therapies. Diagnosis of squamous cell carcinoma of the oral cavity, nasal cavity, paranasal sinuses, nasopharynx, oropharynx, hypopharynx or larynx. Primary or recurrent disease for which no curative or established palliative treatments are amenable WHO performance status of 1 or 2. Received certain other treatments within 4 weeks prior to administration of study drug Previous severe allergic reactions (e.g. angioedema, severe asthma, or anaphylaxis). Skin disease requiring systemic or local corticosteroid therapy. Known brain metastasis or leptomeningeal disease. Signs or symptoms of acute illness. Bacterial, fungal or viral infection. Certain serious medical conditions, including kidney or liver disease, some psychiatric illnesses, myocardial infarction within one year and stomach, lung, heart, hormonal, nerve or blood diseases. Pregnant or breastfeeding women. Women of childbearing age who are unable or unwilling to use an IUD or hormonal birth control during the whole trial. Simultaneous participation in any other trial involving investigational drugs or having participated in a trial within 4 weeks prior to start of trial treatment.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>Head and neck cancer</keyword>
	<keyword>squamous cell carcinoma of the head and neck</keyword>
</DOC>